Akèy › Kansè vejik › Kalifòni › Los Angeles
Etid klinik pou Kansè vejik nan Los Angeles, CA
24 etid pou Kansè vejik ap chèche patisipan nan sit nan ak bò kote Los Angeles (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial
Ap rekriteFaz 2
- Los Angeles General Medical Center, Los Angeles
- USC / Norris Comprehensive Cancer Center, Los Angeles
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Ap rekriteFaz 1
- UCLA Department of Medicine-Hematology/Oncology, Los Angeles
A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011)
Ap rekriteFaz 2
- USC Norris Comprehensive Cancer Center ( Site 0123), Los Angeles
Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial
Ap rekriteFaz 2
- Los Angeles General Medical Center, Los Angeles
- USC / Norris Comprehensive Cancer Center, Los Angeles
- Cedars-Sinai Medical Center, Los Angeles
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
Ap rekriteFaz 1
- Ronald Reagan UCLA Medical Center, Los Angeles
- UCLA Department of Medicine-Hematology/Oncology, Los Angeles
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
Ap rekriteFaz 2
- Keck Medicine of USC Koreatown, Los Angeles
- Los Angeles General Medical Center, Los Angeles
- USC / Norris Comprehensive Cancer Center, Los Angeles
Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer
Ap rekriteFaz 1/2
- START Los Angeles, LLC, Los Angeles
- Los Angeles Cancer Network - Century City, Los Angeles
- (IRB# 26-0433) Ronald Reagan UCLA Medical Center, Drug Information Center, Los Angeles
- ak 1 plis
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
Ap rekriteFaz 3
- TRIO-US (Translational Research in Oncology-US), Los Angeles
- UCLA Hematology/Oncology - Santa Monica, Los Angeles
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas
Ap rekriteFaz 1
- USC/Norris Comprehensive Cancer Center, Los Angeles
Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma
Ap rekriteFaz 2/3
- Research Site, Los Angeles
FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
Ap rekriteFaz 1
- University of California, Los Angeles (UCLA) - Division of Hematology-Oncology, Los Angeles
A Study of MGC026 in Participants With Advanced Solid Tumors
Ap rekriteFaz 1
- The Angeles Clinic and Research Institute, Los Angeles
LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve
Ap rekriteFaz 1/2
- USC/Norris Comprehensive Cancer Center, Los Angeles
- Tower Urology, Los Angeles
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
Ap rekriteFaz 2
- UCLA Downtown Los Angeles Primary & Specialty Care, Los Angeles
- Kaiser Permanente Los Angeles Medical Offices, Los Angeles
- Kaiser Permanente West Los Angeles Medical Center, Los Angeles
- ak 6 plis
A First in Human Study of PLT012 in Participants With Solid Tumor Cancers
Ap rekriteFaz 1
- USC Norris Comprehensive Cancer Center, Los Angeles
Predicting BCG Response
Ap rekriteEtid obsèvasyon
- Cedars-Sinai Medical Center, Los Angeles
- UCLA, Los Angeles
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Ap rekriteFaz 1
- Ronald Reagan UCLA Medical Center, Los Angeles
- The Regents of the University of California, Los Angeles
- UCLA Department of Medicine-Hematology/Oncology, Los Angeles
Study to Assess the Impact of the Urine Test Cxbladder Triage Plus on the Number of Cystoscopies Performed on Patients With Invisible Blood in Their Urine.
Ap rekrite
- Urology Group of Southern California, Los Angeles
- Comprehensive Urology, Los Angeles
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
Ap rekriteFaz 1
- USC - Norris Comprehensive Cancer Center, Los Angeles
A Novel Multiplex ELISA Assay for Surveilling Patients With History of Bladder Cancer
Ap rekriteEtid obsèvasyon
- Cedars-Sinai Medical Center, Los Angeles
A Novel Multiplex ELISA Assay for Evaluating Patients With Microscopic Hematuria for Bladder Cancer
Ap rekriteEtid obsèvasyon
- Cedars-Sinai Medical Center, Los Angeles
- UCLA Medical Center, Los Angeles
Blue Light Cystoscopy With Cysview® Registry
Ap rekriteEtid obsèvasyon
- USC/Norris Comprehensive Cancer Center, Los Angeles
- University of California Los Angeles, Los Angeles
Bladder Fiducial Markers and Multiparametric-MRI (Mp-MRI) to Optimize Bladder Chemo-radiotherapy
Ap rekrite
- Cedars-Sinai Medical Center (CSMC), Los Angeles
- University of California Los Angeles, Los Angeles
Deceased Donor Bladder or Combined Kidney-bladder Transplantation: a Phase 0 First-in-human Study
Ap rekrite
- UCLA, Los Angeles
Etid Kansè vejik nan lòt vil
- New York City, NY35 etid
- Nashville, TN31 etid
- Houston, TX31 etid
- Dallas, TX27 etid
- Washington, DC26 etid
- Boston, MA26 etid
- Baltimore, MD24 etid
- St. Louis, MO22 etid
- Seattle, WA21 etid
- Chicago, IL21 etid
- Edison, NJ21 etid
- Philadelphia, PA21 etid
Lòt etid nan Los Angeles
- Kansè Poumon ki pa ti selil87 etid
- Kansè (tout kalite)74 etid
- Kansè nan tete73 etid
- Kansè pwostat61 etid
- Kansè kolorektal59 etid
- Kansè Metastatik57 etid
- Kansè ovè50 etid
- Kansè poumon45 etid
- Karsinòm selil skuamèz tèt ak kou42 etid
- Kansè pankreyas35 etid
- Kansè Endomèt34 etid
- Melanom34 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.